Axa’s Infinity Pharmaceuticals, Inc. INFI Stock Holding History

Axa’s Portfolio INFI Stock Details INFI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	–	Sell	-25,923	Closed	-$308K	–	1447
2014 Q1	$308K	Buy	25,923 +1,358	+6%	+$18.2K	﹤0.01%	1148
2013 Q4	$339K	Buy	24,565 +1,222	+5%	+$17.3K	﹤0.01%	1141
2013 Q3	$407K	Buy	23,343 +4,718	+25%	+$90.3K	﹤0.01%	1042
2013 Q2	$303K	Buy	+18,625	New	+$576K	﹤0.01%	1057

Other funds holding INFI

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Axa's INFI Position: Q2 2014 in Review

Axa sold out of Infinity Pharmaceuticals, Inc. (INFI) in Q2 2014, closing a stake of 25,923 shares — an estimated $308K sold.

Axa first reported a position in INFI in Q2 2013 and held it in 4 quarters. The position peaked at $407K in Q3 2013. 98 funds tracked by Wall St. Rank hold INFI as of Q2 2014.

Axa reported no remaining Infinity Pharmaceuticals, Inc. position as of Q2 2014 after selling out during the quarter.
Axa sold 25,923 Infinity Pharmaceuticals, Inc. shares in Q2 2014, an estimated $308K.
Axa first reported a position in Infinity Pharmaceuticals, Inc. in Q2 2013 and held it in 4 quarters.
Axa's Infinity Pharmaceuticals, Inc. position peaked at $407K in Q3 2013.
98 funds tracked by Wall St. Rank held Infinity Pharmaceuticals, Inc. as of Q2 2014.

Based on Axa's 13F filing for Q2 2014, filed 13 Aug 2014.